Raloxifene increases serum leptin levels in postmenopausal women: A prospective study

• Published in: American journal of obstetrics and gynecology Vol. 193; no. 2; pp. 347 - 351
• Main Authors: Cakmak, Arzu, Posaci, Cemal, Dogan, Erbil, Caliskan, Sezer, Guclu, Serkan, Altunyurt, Sabahattin
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA Mosby, Inc 01.08.2005; Elsevier
• Subjects: Adult; Aged; Alkaline Phosphatase - blood; Biochemical markers; Biological and medical sciences; Bone and Bones - drug effects; Bone Resorption - prevention & control; Collagen - blood; Collagen Type I; Female; Gynecology. Andrology. Obstetrics; Humans; Insulin-Like Growth Factor I - analysis; Insulin-like growth factor–I; Leptin; Leptin - blood; Medical sciences; Middle Aged; Osteocalcin - blood; Peptides - blood; Postmenopause; Prospective Studies; Raloxifene; Raloxifene Hydrochloride - pharmacology; Selective Estrogen Receptor Modulators - pharmacology; Raloxifene; Insulin-like growth factor–I; Leptin; Biochemical markers; Human; Adipocytokine; Estrogen receptor; Gynecology; Antiestrogen; Biological marker; Biochemistry; Antihormone; Insulin like growth factor 1; Obstetrics; Benzothiophene derivatives; Prospective; Raloxifene Leptin Insulin-like growth factor-I Biochemical markers; Postmenopause; Adult; Female; Serum; Agonist antagonist; Non steroid compound
• ISSN: 0002-9378; 1097-6868
• DOI: 10.1016/j.ajog.2005.01.023

The purpose of this study was to investigate the effect of raloxifene on leptin and insulin-like growth factor–I levels and their relation with the biochemical markers of bone metabolism in postmenopausal women. Sixty-four women were given 60 mg/d raloxifene for 6 months. Serum leptin, insulin-like growth factor–I, alkaline phosphatase, calcium, osteocalcin, and collagen type I cross-link C-telopeptide levels were measured before and after the treatment. The patients were grouped as obese (body mass index, ≥25 kg/m 2) or non-obese (body mass index, <25 kg/m 2). The mean basal leptin level was significantly higher ( P < .001), and the mean cross-link C-telopeptide level was significantly lower ( P = .001) in obese patients. Raloxifene therapy increased leptin levels ( P < .001) and decreased insulin-like growth factor–I, alkaline phosphatase, and cross-link C-telopeptide levels significantly ( P < .001). There was a strong negative correlation between leptin and cross-link C-telopeptide ( r = −0.703; P < .001). Insulin-like growth factor–I was not correlated with any parameter. Raloxifene increases serum leptin levels while decreasing bone resorption in postmenopausal women.